The Health and Food Safety Directorate-General of the European Commission has launched a call for expressions of interest to represent civil society in the Management Board of the European Medicines Agency (EMA). Two members representing patients’ organizations, one member representing healthcare professionals’ organizations and one member representing veterinarians’ organizations will be appointed for a renewable three-year period. The term of office of the current members expires on March 20, 2016. Expressions of interest should be submitted to the European Commission no later than September 20, 2015, either by e-mail or post.
The role of the civil society members of EMA Management Board is to ensure that the views and needs of patients, healthcare professionals, and veterinarians are taken into account in the discussions and decisions taken by the board. Appointees will be involved in the board’s procedures in the same way as other board members. They are expected to attend the quarterly meetings of the Management Board at the EMA, examine documents, contribute to discussions, and make comments with a specific focus on the group they represent.
The Management Board is the EMA's governance body. It has a supervisory role with general responsibility for budgetary and planning matters. This includes, in particular: the appointment of the Executive Director; the adoption of annual and multi-annual work programs of the EMA and the annual report on the agency's activities; the adoption of opinions on the rules of procedure of the scientific committees of the EMA as well as the adoption of procedures for the performance of scientific services; the adoption of the internal financial provisions; and the adoption of the EMA budget.
The EMA Management Board is composed of one representative of each member state of the European Union, two representatives of the European Commission, two representatives of the European Parliament, and four civil society representatives. The four civil society board members are appointed by the Council of the European Union, after consultation of the European Parliament and based on a list drawn up by the European Commission.
Source: European Medicines Agency